Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SLDB 
Solid Biosciences LLC (SLDB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: SLDB (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15.58
1 Year Target Price $15.58
| 7 | Strong Buy |
| 5 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 140.32% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 419.71M USD | Price to earnings Ratio - | 1Y Target Price 15.58 |
Price to earnings Ratio - | 1Y Target Price 15.58 | ||
Volume (30-day avg) 12 | Beta 2.55 | 52 Weeks Range 2.41 - 8.10 | Updated Date 09/14/2025 |
52 Weeks Range 2.41 - 8.10 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.79 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.35% | Return on Equity (TTM) -68.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 174655292 | Price to Sales(TTM) 3.65 |
Enterprise Value 174655292 | Price to Sales(TTM) 3.65 | ||
Enterprise Value to Revenue 1.16 | Enterprise Value to EBITDA -3.69 | Shares Outstanding 77869104 | Shares Floating 37620106 |
Shares Outstanding 77869104 | Shares Floating 37620106 | ||
Percent Insiders 0.52 | Percent Institutions 105.94 |
Upturn AI SWOT
Solid Biosciences LLC
Company Overview
History and Background
Solid Biosciences LLC (SLDB) was founded in 2013. It's a biotechnology company focused on developing therapies for Duchenne muscular dystrophy (DMD). Their history includes clinical trials, setbacks, and strategic shifts in their DMD program.
Core Business Areas
- DMD Therapeutics Development: Focuses on developing gene therapies and other treatments for Duchenne muscular dystrophy.
Leadership and Structure
The leadership team includes individuals with experience in biotechnology and pharmaceutical development. The company has a typical corporate structure with a board of directors and various management teams.
Top Products and Market Share
Key Offerings
- SGT-001 (Previously):: Was Solid's lead gene therapy candidate for DMD. Clinical trials faced challenges. Competitors include Sarepta Therapeutics (SRPT), PTC Therapeutics (PTCT), and BioMarin Pharmaceutical (BMRN). SGT-001 faced FDA clinical hold issues which significantly impacted market prospects.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, with significant investment and regulatory attention. DMD therapies are in high demand due to the severity of the disease and limited treatment options.
Positioning
Solid Biosciences is a smaller player in the DMD market compared to established companies like Sarepta. Their competitive advantage lies in their gene therapy technology and focus on a specific subset of DMD patients.
Total Addressable Market (TAM)
The DMD market is estimated to be in the billions of dollars. Solid Biosciences' TAM is dependent on the success of their clinical trials and regulatory approvals. Given the challenges and restructuring, their position against the TAM is weak.
Upturn SWOT Analysis
Strengths
- Proprietary gene therapy platform
- Focused on Duchenne muscular dystrophy
- Experienced management team
Weaknesses
- Clinical trial setbacks and regulatory hurdles
- Limited financial resources compared to larger competitors
- Reliance on a single therapeutic area
Opportunities
- Potential for breakthrough therapies in DMD
- Strategic partnerships with larger pharmaceutical companies
- Expansion into other neuromuscular disorders
Threats
- Competition from established players in the DMD market
- Regulatory risks and clinical trial failures
- Financial constraints and need for additional funding
Competitors and Market Share
Key Competitors
- SRPT
- PTCT
- BMRN
Competitive Landscape
Solid Biosciences faces strong competition. Sarepta has established therapies, while PTC and BioMarin also offer DMD treatments. Solid Biosciences' success depends on differentiating their therapies and overcoming clinical hurdles.
Growth Trajectory and Initiatives
Historical Growth: Solid Biosciences' growth has been marked by clinical trial advancements and setbacks, affecting stock performance and company valuation.
Future Projections: Future growth relies on successful clinical trials and regulatory approval of their therapies. Analyst projections vary widely depending on the progress of their pipeline.
Recent Initiatives: Focus on next generation therapies and strategies to improve their outcomes and development pipeline.
Summary
Solid Biosciences is a high-risk, high-reward biotech company focused on DMD. Their future hinges on overcoming clinical challenges and securing regulatory approval. Recent setbacks have negatively impacted the company, and they must continue to develop and execute their strategy to compete with larger, more established companies. Investors should monitor their clinical trial progress and financial stability closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry publications
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share percentages are estimates and can vary. The information provided is based on available data and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Solid Biosciences LLC
Exchange NASDAQ | Headquaters Charlestown, MA, United States | ||
IPO Launch date 2018-01-26 | President, CEO & Director Mr. Alexander G. Cumbo | ||
Sector Healthcare | Industry Biotechnology | Full time employees 100 | Website https://www.solidbio.com |
Full time employees 100 | Website https://www.solidbio.com | ||
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.